Issue
Korean Journal of Chemical Engineering,
Vol.27, No.5, 1538-1546, 2010
Systematic evaluation and optimization of crystallization conditions for vancomycin purification
This study describes the evaluation and optimization of a crystallizing process capable of efficiently purifying vancomycin in high purity and yield. In particular, we observed how the main process parameters influenced the formation of crystals, determined their morphology, and monitored purity and yield. Acetone was shown to be more effective than alcohol solvents for the crystallization of vancomycin. The optimal distilled water/acetone ratio, storage temperature, storage time, pH, conductivity, initial vancomycin concentration and stirrer velocity were shown to be 1 : 3.5 (v/v), 10 ℃, 24 h, pH 2.5, 20 ms/cm, 0.1 g/mL, and 640 rpm, respectively. Temperature had a decisive influence on crystal formation; crystals were successfully produced at 10 ℃, while at other temperatures, conglomeration, disintegration and cohesion occurred. Crystal growth developed over time and was complete at about 24 h. Vancomycin purity remained at about 97.0% irrespective of storage time while the yield increased over time, reaching a maximum of 95.0% at around 24 h, after which there was no substantial change. Crystallization occurred over a certain range of pH (2.5-3.0), but purity and yield were highest at pH 2.5. When the pH was outside this range, a conglomeration (gelation) phenomenon prevented the efficient production of crystals. Vancomycin crystals were produced irrespective of the stirrer velocity, which had no influence on purity; however, the highest yield of vancomycin was obtained at 640 rpm.
[References]
  1. Yan H, Qi D, Cheng X, Song Z, Li W, He B, J. Antibio., 51, 750, 1998
  2. Griffith RS, J. Antimicrob. Chemother., 14, 1, 1984
  3. Kim SI, Han CY, Jung HS, Lee JS, Ok SY, Kim SC, Korean J. Anesthesio., 51, 727, 2006
  4. Lee JW, Jung YT, Suh JW, Lee KS, US Patent 7,018,814, 2006
  5. Javadzadeh Y, Mohammadi A, Khoei NS, Nokhodchi A, Acta Pharm., 59, 187, 2009
  6. Kim SI, Jeong KE, Jeong SY, Kim CU, J. Korean Oil Chem. Soc., 25, 232, 2008
  7. Kim KJ, Prospect Ind. Chem., 4, 1, 1001
  8. McCormick MH. Wild GM, US Patent 4,440,753, 1984
  9. Glass SLE, Johnson CW, Spencer JL, US Patent 4,845,194, 1989
  10. Krishnan L, US Patent 5,235,037, 1993
  11. Kim WS, Lee EK, Korean J. Biotechnol. Bioeng., 20, 164, 2005
  12. United States Pharmacopeia (USP 29): Vancomycin hydrochloride, United State Pharmacopeial Convention, Inc., 2006
  13. Lee KS, Bang YK, Korean Ind. Chem. News, 10(5), 31, 2007
  14. Kim DY, Paul M, Repke JU, Wozny G, Yang DR, Korean J. Chem. Eng., 26(5), 1220, 2009
  15. Kang KS, Lee SI, Lee TJ, Narayan R, Shin BY, Korean J. Chem. Eng., 25(3), 599, 2008
  16. Kim CK, Lee BC, Lee YW, Kim HS, Korean J. Chem. Eng., 26(4), 1125, 2009
  17. Grahek R, Bastarda A, European Patent EP 1,824,874, 2009
  18. Kim WS, Korean Ind. Chem. News, 10(5), 9, 2007
  19. Claudius JS, Neau SH, Int. J. Pharm.., 168, 41, 1998
  20. Catt HR, Hayes HB, European Patent EP 0,323,150, 1993